Company Description
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide.
It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.
The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries.
In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin.
Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures.
It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001.
LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
| Country | United States |
| Founded | 1983 |
| IPO Date | Oct 19, 2006 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 630 |
| CEO | George W. LeMaitre |
Contact Details
Address: 63 Second Avenue Burlington, Massachusetts 01803 United States | |
| Phone | 781-221-2266 |
| Website | lemaitre.com |
Stock Details
| Ticker Symbol | LMAT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001158895 |
| CUSIP Number | 525558201 |
| ISIN Number | US5255582018 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| George W. LeMaitre | Chairman and Chief Executive Officer |
| David B. Roberts | President and Director |
| Joseph P. Pellegrino Jr. | Chief Financial Officer, Treasurer, Secretary and Director |
| Trent G. Kamke | Senior Vice President of Operations |
| Dr. George D. LeMaitre | Founder and Chairman of Scientific Advisory Board |
| David C. Hissong | General Counsel |
| Kimberly L. Cieslak | Vice President of Marketing |
| Daniel J. Mumford | Director of Human Resources |
| Ryan H. Connelly | Senior Vice President of Advanced Manufacturing Engineering |
| Andrew Hodgkinson | Senior Vice President of Clinical, Regulatory and Quality Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | ARS | Filing |
| Apr 16, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 8, 2024 | 144 | Filing |
| Mar 5, 2024 | 144 | Filing |
| Mar 1, 2024 | 144 | Filing |
| Feb 29, 2024 | 144 | Filing |
| Feb 29, 2024 | 144 | Filing |
| Feb 29, 2024 | 10-K | Annual Report |
| Feb 29, 2024 | 144 | Filing |
| Feb 27, 2024 | 8-K | Current Report |